SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Stomach - Gastric Cancer - Stomach Cancer Aetiology Written by Dr Sebastian Zeki

Stomach Cancer Aetiology

Cytokine polymorphismsIL-1 inhibits gastric acid secretion and gets upregulated by H.pylori.Polymorphisms (IL-1B-31T and IL-1RN*2) are especially associated with low acid secretion and gastric atrophy. More common in Africans.Other proinflammatory genotypes of TNFalpha and IL-10 are also associated.IFNG1R polymorphisms are associ-ated with high H.pylori antibodies and more prevalent in Africans (may explain increased prevalence in Africa of H. pylori but decreased pathogenicity. Free radical production Decreased ascorbate Its usual role is protective.It blocks nitrosation.It scavenges free radicals.It reduces pH. Increased gastrin (compensates for increased pH) Cell proliferation Increased N-nitroso compounds Atrophic Decreased acid secretion Inflammation Increased nitrate-reducing bacteria proliferation Neutrophil attractionIt produces inducible NOS with NO and free radical production) Epithelial cell damage Loss of parietal cell mass + Causes Free radical production Correa Hypothesis (intestinal type gastric ca) Gastric cancer Pathogenesis H. pylori related Causes acute and chronic gastritis Normal Acute gastritis Chronic gastritis Atrophic gastritis Intestinal metaplasia (IM) Types:-Type 1 (small intestine type mucosa).-Type 2.-Type 3 (colonic type mucosa). Dysplasia Types:Low grade (progress to ca in 10%).High grade (progress to ca in 70%). Early gastric cancer (limited to mucosa and submucosa regardlessof lymph node involvement) Late gastric cancer These are not always premalignant Written by Dr Sebastian Zeki

Related Stories

•Latent category analysis of psychosocial characteristics of gastric cancer patients: an association study with quality of life and survival prognosis

•Aetiologies and prognosis of small bowel obstruction in virgin abdomen: a retrospective cohort study

•Oncogenic SOX9-TRAIP signaling drives gastric cancer progression by mediating the degradation of the CPEB3-mTORC1 tumor suppressor axis

•RNA m(6)A modification is a driver and therapeutic target in gastric cancer

•Identification of a biologically coherent three gene immune signature predictive of immunotherapy benefit in gastric adenocarcinoma